Magle Chemoswed Holding
16.50 SEK
+4.43 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+4.43 %
-6.25 %
+4.43 %
-14.06 %
-36.54 %
-55.65 %
-39.54 %
-57.69 %
-17.88 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
340.71M SEK
Turnover
45.9K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.38
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.2
2026
Annual report '25
18.5
2026
Interim report Q1'26
26.5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
BioStock: Magle: ”We’re looking towards Magle 2.0”
Magle Chemoswed Holding AB announces change of Certified Adviser to Redeye
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools